| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components
|
Wheeler, Allison P.
|
|
|
8 |
9 |
p. 2290-2299
|
artikel
|
| 2 |
Anticoagulation and antiplatelet agent use among patients with von Willebrand disease and cardiac disease
|
Merz, Lauren E.
|
|
|
8 |
9 |
p. 2244-2247
|
artikel
|
| 3 |
Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-ENL–mediated leukemia
|
Nakamura, Akihide
|
|
|
8 |
9 |
p. 2193-2206
|
artikel
|
| 4 |
BTK inhibitors in CLL: second-generation drugs and beyond
|
Tam, Constantine
|
|
|
8 |
9 |
p. 2300-2309
|
artikel
|
| 5 |
Combined effect of unrelated donor age and HLA peptide-binding motif match status on HCT outcomes
|
Mehta, Rohtesh S.
|
|
|
8 |
9 |
p. 2235-2242
|
artikel
|
| 6 |
Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
|
Allen, Cecily
|
|
|
8 |
9 |
p. 2279-2289
|
artikel
|
| 7 |
C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma
|
Cheung, Coty Hing Yau
|
|
|
8 |
9 |
p. 2217-2234
|
artikel
|
| 8 |
Dissecting causal links between gut microbiota, inflammatory cytokines, and DLBCL: a Mendelian randomization study
|
Jiang, Peiyao
|
|
|
8 |
9 |
p. 2268-2278
|
artikel
|
| 9 |
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile
|
Zeng, Zhihong
|
|
|
8 |
9 |
p. 2059-2073
|
artikel
|
| 10 |
EBV+ nodal T/NK-cell lymphoma associated with clonal hematopoiesis and structural variations of the viral genome
|
Kato, Seiichi
|
|
|
8 |
9 |
p. 2138-2147
|
artikel
|
| 11 |
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
|
Carrillo de Albornoz, Sara
|
|
|
8 |
9 |
p. 2259-2267
|
artikel
|
| 12 |
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106.
|
|
|
|
8 |
9 |
p. 2243
|
artikel
|
| 13 |
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study
|
Samples, Laura
|
|
|
8 |
9 |
p. 2085-2093
|
artikel
|
| 14 |
Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia
|
Richardson, Kris
|
|
|
8 |
9 |
p. 2133-2137
|
artikel
|
| 15 |
Influence of ATLG serum levels on CD3/CD19-depleted hematopoietic grafts and on immune recovery in pediatric haplo-HSCT
|
Maier, Claus-Philipp
|
|
|
8 |
9 |
p. 2160-2171
|
artikel
|
| 16 |
Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT
|
Pandey, Nilesh
|
|
|
8 |
9 |
p. 2104-2117
|
artikel
|
| 17 |
Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?
|
Sánchez-Salinas, Mario Andrés
|
|
|
8 |
9 |
p. 2130-2132
|
artikel
|
| 18 |
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
|
Bantilan, Kurt S.
|
|
|
8 |
9 |
p. 2172-2181
|
artikel
|
| 19 |
Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP
|
Saito, Kenki
|
|
|
8 |
9 |
p. 2151-2159
|
artikel
|
| 20 |
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia
|
Tarlock, Katherine
|
|
|
8 |
9 |
p. 2094-2103
|
artikel
|
| 21 |
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab
|
Chandrakasan, Shanmuganathan
|
|
|
8 |
9 |
p. 2248-2258
|
artikel
|
| 22 |
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia
|
Myers, Regina M.
|
|
|
8 |
9 |
p. 2182-2192
|
artikel
|
| 23 |
Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma
|
Reyes, Kevin R.
|
|
|
8 |
9 |
p. 2207-2216
|
artikel
|
| 24 |
Spencer A, Moreau P, Mateos M-V, et al. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024;8(2):388-398.
|
|
|
|
8 |
9 |
p. 2148-2150
|
artikel
|
| 25 |
Targeting metabolic dependencies in JAK2-V617F–driven MPNs
|
Wolf, Dominik
|
|
|
8 |
9 |
p. 2310-2311
|
artikel
|
| 26 |
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN
|
Usart, Marc
|
|
|
8 |
9 |
p. 2312-2325
|
artikel
|
| 27 |
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract
|
DeFilipp, Zachariah
|
|
|
8 |
9 |
p. 2074-2084
|
artikel
|
| 28 |
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
|
Kleinstern, Geffen
|
|
|
8 |
9 |
p. 2118-2129
|
artikel
|
Tijdschrift beschrijving